Redeye provides an update following SenzaGen’s Q1 2025 report. The quarterly figures came in a bit below our expectations; however, we argue that the long-term outlook and our investment case are intact. Based on the report, we make some downward changes to our sales estimates, rendering an updated fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/